Education Day
Thursday, November 17, 2011

Stereotactic Radiosurgery and Radiation Biology in the CNS
Grand Ballroom A-D

8:10-8:20 am Welcome – Education Day
Introduction
Co-Chairs: Eric Chang, Arjun Sahgal, Jason Sheehan

Morning Session: Radiosurgery and Stereotactic Body Radiation Therapy for the CNS

8:20-8:40 am Introduction to Technology of Radiosurgery and Stereotactic Body Radiation Therapy: Evolution from Brain to Spine
Arjun Sahgal

8:40-9:00 am Introduction to Spine Stereotactic Body Radiation Therapy: What is it? What are the outcomes? What are the issues, controversies?
Arjun Sahgal

9:00-9:20 am Radiosurgical decompression of spinal cord compression
Sam Ryu

9:20-9:40 am Surgery for malignant epidural spinal cord compression
Ziya Gokaslan

9:40-10:00 am Normal tissue tolerance and spinal radiosurgery: Lessons from preclinical studies
Paul Medin

10:00-10:20 am Break

10:20-10:40 am Stereotactic body radiation therapy and minimally invasive surgery for spine: a new paradigm
Peter Gerszten

10:40-11:00 am Skull Base Radiosurgery: Current knowledge and unanswered questions
Jason Sheehan

11:00-11:20 am Radiation therapy for brain metastases based on the currently available evidence
Eric Chang

11:20-11:40 am Radiosurgery for gliomas
Michael Vogelbaum

11:40-12:00 pm Radiosurgery for the postoperative resection cavity
Paul Brown

12:00 - 1:00 pm Boxed lunches

Afternoon Session: Radiation, Biology, and the CNS

1:00-1:30 pm Improving radiation therapy in the brain using DNA repair inhibitors
Thomas Helleday

1:30-2:00 pm Nanodevices and radiation therapy, ways around the barrier?
Mohamed Khan

2:00-2:30 pm MRgFUS induced blood brain barrier disruption and novel drug delivery for brain tumors
Nathan McDonnell

2:30-3:00 pm Radiation-induced non-target response: Mechanism and clinical implication
Tom Hei

3:00-3:15 pm Break

3:15-3:45 pm Ultrasound, high- and low-dose radiation and apoptosis
Greg Czarnota

3:45-4:15 pm Radiobiology of radiosurgery, response modifiers, and radionecrosis
Sam Chao

4:15-4:45 pm Mechanisms of radiation associated secondary malignancies
Jean Nakamura

SNO thanks Eisai, Inc., for their support of the 2011 Education Day
## Concurrent Education Day Session
### Quality of Life/Symptom Management

**Grand Ballroom E-G**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00-8:10</td>
<td>Welcome – Education Day</td>
<td>Mary Lovely</td>
</tr>
<tr>
<td>8:10-9:10</td>
<td>Neuropsychiatric Interventions</td>
<td></td>
</tr>
<tr>
<td>8:10-9:10</td>
<td>Differential Diagnosis of Cognitive and Behavioral Problems</td>
<td>Manmeet Ahluwalia and Michael Glantz</td>
</tr>
<tr>
<td>9:10-9:30</td>
<td>Mood and Anxiety Disorders in Patients with Brain Tumors</td>
<td>Brian Appleby</td>
</tr>
<tr>
<td>9:30-9:50</td>
<td>Seizures and Pseudoseizures</td>
<td>Robert Cavaliere</td>
</tr>
<tr>
<td>9:50-10:00</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:00-10:20</td>
<td>Quality of Life Interventions</td>
<td></td>
</tr>
<tr>
<td>10:00-10:20</td>
<td>Driving and other Safety Issues</td>
<td>Mark Shaffrey</td>
</tr>
<tr>
<td>10:20-10:40</td>
<td>Management of Memory and Attention Deficits</td>
<td>Jennie Rexer</td>
</tr>
<tr>
<td>10:40-11:00</td>
<td>Management of Fatigue and Sleep Disorders</td>
<td>Terri Armstrong</td>
</tr>
<tr>
<td>11:00-11:20</td>
<td>Caregiver Burden and Caregiver Interventions</td>
<td>Martin Klein</td>
</tr>
<tr>
<td>11:20-11:40</td>
<td>Management of Disinhibition and Dysexecutive Syndrome</td>
<td>Caroline Racine</td>
</tr>
<tr>
<td>11:40-12:00</td>
<td>Delirium</td>
<td>Susan B. Turkel</td>
</tr>
<tr>
<td>12:00 - 1:00</td>
<td>Boxed lunch</td>
<td></td>
</tr>
<tr>
<td>1:00-1:20</td>
<td>Quality of Life and SNO</td>
<td></td>
</tr>
<tr>
<td>1:00-1:20</td>
<td>Needs of SNO Membership Regarding QOL: Results of a SNO Survey</td>
<td>Alixis VanHorn</td>
</tr>
<tr>
<td>1:20-1:40</td>
<td>General Discussion: Quality of Life Programs</td>
<td></td>
</tr>
</tbody>
</table>

## Concurrent Education Day Afternoon Session
### Clinical Trials Course for Young Investigators

**Grand Ballroom E-G**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:45-2:00</td>
<td>Introduction, Overview, Historical Perspective</td>
<td>Susan Chang</td>
</tr>
<tr>
<td>2:00-2:20</td>
<td>Phase 0 and I Trials: How they can expedite the clinical research agenda</td>
<td>Howard Colman</td>
</tr>
<tr>
<td>2:20-2:40</td>
<td>Challenges in Phase II Trial Design</td>
<td>Eva Galanis</td>
</tr>
<tr>
<td>2:40-3:00</td>
<td>Overview of the Basics of Phase III Trials</td>
<td>Mark Gilbert</td>
</tr>
<tr>
<td>3:00-3:15</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>3:15-3:35</td>
<td>Challenges of Response Assessment/Endpoint Evaluations for Surgically Based Studies</td>
<td>Michael Vogelbaum</td>
</tr>
<tr>
<td>3:35-3:55</td>
<td>Responsibilities of a PI</td>
<td>Manish K. Aghi</td>
</tr>
<tr>
<td>3:55-4:20</td>
<td>Overview of Regulatory Requirements (Institutional and FDA)</td>
<td>James Markert</td>
</tr>
<tr>
<td>4:20-4:45</td>
<td>Personal experience in conducting a Clinical Trial: Pearls and Pitfalls</td>
<td>E. Antonio Chiocca</td>
</tr>
<tr>
<td>4:45-4:50</td>
<td>Summary, Additional Educational Resources</td>
<td>Mark Linskey</td>
</tr>
</tbody>
</table>

## Industry Sponsored Satellite Symposia

(Not sponsored by The University of Texas MD Anderson Cancer Center)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:00-7:15</td>
<td>Glioblastoma Multiforme: Applying Best Practices to Clinical Cases</td>
<td>Grand Ballroom A-D</td>
</tr>
<tr>
<td>5:00-7:15</td>
<td>Selection to Optimize Outcomes for Skull Base Tumor Patients</td>
<td>Terrace Rooms A-F</td>
</tr>
</tbody>
</table>

## Welcome Reception

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30-10:00</td>
<td>Welcome Reception</td>
<td>Pool patio</td>
</tr>
</tbody>
</table>
**Sunrise Sessions  7:00-8:00 am**

### Viral Gene Therapy  Salon VII-VIII
- Convection-enhanced delivery of oncolytic adenovirus in gliomas  
  *Clemens Dirven*
- Pre-clinical development and clinical testing of oncolytic measles virus  
  *Evanthia Galanis*
- Retroviral replicating vectors for cancer gene therapy  
  *Noriyuki Kasahara*

### Surgery for Non-malignant Skull Base Tumors  Terrace A-C
- Endoscopic versus open approaches to the anterior skull base: A Balanced Dialogue  
  *Ted Schwartz*
- Open skull base approaches  
  *Jacques Morcos*

### Cancer Cell Metabolism  Harbor Room
- Targeting altered cellular metabolism in EGFR/PI3K-activated glioblastomas  
  *Paul Mishel*
- The mitochondria and tumor cell growth  
  *Rolph Deberardinis*
- Determining how fat fuels growth in glioma  
  *Steven Bensinger*

### Advances in Anatomic, Metabolic and Physiologic Neuroimaging  Pacific Room
- Genomic correlates of imaging biomarkers  
  *Whitney Pope*
- Multiparametric physiological imaging in glioblastoma  
  *Ben Ellingson*
- Perfusion MRI in glioma  
  *Kathleen Schmainda*
- Non-FDG PET for Glioma  
  *Jeorg Tonn*

**Plenary Session  8:15-noon**

### Grand Ballroom
- Welcome & Meeting Introduction  
  *Co-Chairs: Timothy Cloughesy and Michael Vogelbaum*

### Top Abstracts 1

**Moderated by William Weiss and E. Antonio Chiocca**

- Metabolic modulation of GBMs by depleting Hexokinase II: potentiating the effect of standard therapies  
  *Alenoush Vartanian*
- Targeting EGFR/PI3K/Akt regulated SREBP-1/LDLR mediated cholesterol metabolism to treat GBM  
  *Deliang Guo*

**Break**

- RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM)  
  *Mark R. Gilbert*
- A combined molecular clinical predictor of survival validated with the RTOG-0525 cohort  
  *Erik P. Sulman*
- Clinical utility of G-CIMP and IDH1 status as dual prognostic markers in glioblastoma  
  *Kenneth D. Aldape*

### President’s address and introduction to the Victor Levin Lecture  
**Frederick F. Lang**

### Victor Levin Award Lecture  
*Kenneth D. Aldape*

**Boxed Lunch**

- Young Investigators Roundtables  Pacific Room  
  Supported by Genentech
- International Outreach (members welcome)  Harbor Room
- Industry Supported Event: Current state of the art: Vaccine development in the treatment of GBM  
  Terrace Room  (Not sponsored by The University of Texas MD Anderson Cancer Center)
Concurrent Sessions  1:00-3:00 pm

Cell Biology and Micro-Environment
Grand Ballroom A-D
Moderated by Peter Forsyth and Candece Gladson

1:00 pm  RB-05  Understanding radiation injury and neurogenesis using a novel astrocyte-specific inducible mouse model
Robert Bachoo

1:15 pm  CB-42  Tumor associated mesenchymal stromal cells increase proliferation and maintain stemness of glioma stem cells through the IL6/STAT3 pathway
Anwar Hossain

1:30 pm  SC-11  Controlling the migration of GBM cells: lessons from neurogenic niches
Linda Chen

1:45 pm  CB-18  SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans
Shi-Yuan Cheng

2:00 pm  CB-52  Molecular determinants of dichotomy between proliferation and invasion of glioma cells
Harshil Dhruv

2:15 pm  CB-70  Asymmetry-defective oligodendrocyte progenitors are glioma precursors
Claudia Petritsch

2:30 pm  CB-21  Targeted disruption of Stat3 signaling inhibits tumor growth and brain metastases by Caveolin-1 upregulation
Suyun Huang

2:45 pm  CB-33  Decrypting Chromosome 10q Deletion in Glioblastoma. An Interspecies Comparison of Gene Copy Number Alterations
Adam M. Sonabend

Immunology/Immunotherapeutics
Grand Ballroom E-G
Moderated by Alan Waziri and Linda Liau

1:00 pm  IM-03  Long-term follow-up of ACT III: A Phase II trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma
Rose K. Lai

1:15 pm  IM-12  An in vivo immunotherapy screen identifies Fc-mOX40L as a potent drug capable of causing regression of large murine gliomas
Katherine A. Murphy

1:30 pm  IM-15  Phase 2 study of gene mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma
E. A. Chiocca

1:45 pm  IR-03  Intense human cytomegalovirus (HCMV) immune response in glioblastoma patients: A prognostic factor for survival
Adelaida Garcia-Velasco

2:00 pm  IM-16  Combining Anti-PD-1 (B7-H1) immunotherapy with stereotactic radiosurgery in a mouse orthotopic glioblastoma model
Jing Zeng

2:15 pm  IM-25  Radiosurgery for melanoma brain metastases in the Ipilimumab era: Longer survival is possible
Jonathan P. Knisely

2:30 pm  IR-05  Interleukin-4 receptor α-chain promotes the immunosuppressive activity of glioma-infiltrating monocytes
Gary Kohanbash

2:45 pm  IM-18  Dendritic cell vaccine therapy for patients with recurrent glioblastoma: A single-institution pooled analysis of four trials
Jethro Hu

3:00 pm  Break

Concurrent Sessions  3:15-5:00 pm

Preclinical
Grand Ballroom A-D
Moderated by Jann Sarkaria and Gelareh Zadeh

3:15 pm  AI-24  The role of bone marrow derived cells in tumor stage dependant neo-vascularisation
Kelly Burrell

3:30 pm  CB-14  Therapeutic potential of AZD1480 for the treatment of human glioblastoma
Braden C. McFarland

3:45 pm  RB-04  Bone marrow derived progenitors and ionizing radiation in normal brain
Kelly Burrell

4:00 pm  ET-55  BRaf Inhibitor PLX4720 is a radiosensitizer in human malignant astrocytomas expressing the BRaf V600E mutation
Tina Dasgupta

4:15 pm  ET-06  Preclinical studies reveal mechanisms of response and adaptation of proneural glioblastoma to Sunitinib
Liang Lei

4:30 pm  AI-13  Optimization of glioma treatment through suppression of proinvasive RGS4 by mTOR inhibition
Markus Weller

4:45 pm  ET-22  Active efflux at the blood brain barrier limits: Effective pharmacotherapy of malignant glioma
John Ohlfest
Radiology
Grand Ballroom E-G
Moderated by Whitney Pope and Sarah Jost

3:15 pm  ST-40 Confocal Microscopic Fluorescence Imaging of Gliomas
Sameer Sheth

3:30 pm  RA-16 Diffusion imaging parameters vary with treatment regimen for patients with newly diagnosed glioblastoma multiforme
Laleh Jalilian

3:45 pm  RA-37 Correlation of MRI imaging characteristics with patterns of progression in patients with recurrent glioblastoma treated with bevacizumab
Whitney B. Pope

4:00 pm  RA-06 Functional diffusion maps in FLAIR abnormal regions predict survival in both newly diagnosed glioblastoma treated with radiochemotherapy and recurrent glioblastoma treated with bevacizumab
Benjamin M. Ellingson

4:15 pm  RA-31 Radiogenomic mapping in GBM in patients with high versus low edema/tumor infiltration using an image-genomic analysis of 12, 764 genes and 555 microRNAs
Rivka R. Colen

4:30 pm  OM-34 Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade glioma
Llewellyn Jalbert

4:45 pm  NO-52 FET-PET positive brain lesions: A comparison of 18F-FET-PET, MRI and histopathological findings
Martha Nowosielski

Industry Satellite Symposia  5:00-7:15 pm
(Not sponsored by The University of Texas MD Anderson Cancer Center)

5:00-7:15 pm Glioblastoma: Expert Perspectives on Current Standards of Care and Novel Approaches
Supported by Merck
Grand Ballroom A-D

5:00-7:15 pm Adaptive Hybrid Surgery: Optimizing Outcomes for Benign Skull Base Tumor Patients
Supported by Brainlab
Grand Ballroom E-G

Saturday, November 19, 2011
7:00-9:00 am  Breakfast in the Foyer

Sunrise Sessions  7:00-8:00 am

Brain Cancer Cells of Origin Salon VII-VIII
- Non-stem cell origin for oligodendroglioma
  William Weiss
- Glioblastoma cancer stem-like cells contribute to tumor endothelium
  Vivian Tabar
- Conflict of interest: An oppositional relationship between stemness and p53 in malignant glioma
  Chuck Stiles

Intraoperative Surgical Adjuncts for Visualizing Tumor
Terrace A-C
- Laser Interstitial Thermal Therapy
  Gene Barnett
- 5-ALA
  Constantinos Hadjipanayis
- Nanoparticles
  Steven Toms

Neurological Complications of Cancer Therapy
in the CNS  Pacific Room
This session is jointly organized by SNO and the American Academy of Neurology
- Introduction
  Lisa Rogers
- Complications of radiotherapy and chemotherapy
  Lisa DeAngelis
- Effect of RT and chemotherapy on neural stem stems and cognitive function
  Michelle Monje
- Neurologic complications of targeted molecular therapies
  Patrick Wen

Diffuse Intrinsic Pontine Gliomas and Other Pediatric Astrocytic Tumors  Harbor Room
- Current concepts for low grade and high grade glioma and diffuse brainstem glioma: Issues and challenges
  Michael Prados
- Diffuse infiltrating brainstem glioma, current approaches and new strategies
  Mark Kieran
- Low grade glioma in children/implications of BRAF alterations
  Theodore Nicolaides
- High grade astrocytoma/glioma in children, current approaches and new strategies
  Tobey MacDonald

Neuro-Oncology in Korea: A KSNO/SNO Joint Session
Salon I
- Foundation History of the Korean Society for Neuro-Oncology
  Seung Hoon Lee
- Plan for Multicenter Clinical Trial for Standardization of Therapeutic Guidelines in Malignant Gliomas in Korea  
  
  Yong Kil Hong

- Temozolomide for Brain Tumors: Is There Room for Expansion?  
  
  Mark Gilbert

- Practice Guidelines for Gliomas  
  
  Mark Linskey

### Plenary Session  8:15-12:0 pm  
**Grand Ballroom**

### Top Abstracts 2  
**Moderated by Ingo Mellinghoff and Ian Pollack**

8:15 am  QL-03  
Clinical utility of Quality of Life (QOL) and symptom assessment as prognostic factors for survival and measures of treatment effects on RTOG 0525  
Terri Armstrong

8:30 am  EP-08  
Inherited variants impact survival in uniformly-treated glioblastoma patients  
Yuanyuan Xiao

8:45 am  PC-02  
Efficacy of bevacizumab + CPT-11 in children with recurrent low grade glioma (LGG) - a Pediatric Brain Tumor Consortium study  
Sridharan Gururangan

9:00 am  PC-07  
Cumulative cisplatin dose does not correlate with event-free and overall survival outcomes in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy  
Amulya A. Nageswara Rao

9:15 am  PL-10  
Transposoncogenetics implicates a novel RhoGAP and other genetic drivers of primitive neuroectodermal tumors  
David A. Largaespada

9:30 am  PL-14  
Identifying genes that promote leptomeningeal dissemination in Sonic Hedgehog-driven murine medulloblastoma  
Daniel W. Fults

9:45 am  Lifetime Achievement Award  
Jerome Posner

10:05 am Break

10:25 am SC-21  
Glioblastoma stem cell subtypes display different patterns in neural differentiation, growth, and invasiveness  
Jun Fu

10:40 am IR-01  
Cytomegalovirus subverts the monocyte lineage to become glioma propagating  
Kristine Dziurzynski

10:55 am ET-42  
NF1-deficiency defines a subgroup of GBM sensitive to clinically available MEK inhibitors  
Wendy See

11:10 am SC-26  
Contribution of microglia to radioresistance and mesenchymal differentiation in glioblastoma  
Krishna Bhat

11:25 am  Keynote Lecture  
Introduction: Timothy Cloughesy  
Using Cancer Genetics to Guide Drug Target Selection: Lessons from Gleevec and Beyond  
William G. Kaelin Jr., MD  
Professor of Medicine, Harvard Medical School

### Noon- 1:00 pm  Boxed Lunch

- Industry Supported Event: Current state of the art: Vaccine development in the treatment of GBM  
  Terrace Room (Not sponsored by The University of Texas MD Anderson Cancer Center

- SNO Business Meeting  
  Pacific Room

### Concurrent Sessions  1:00-3:00 pm  
**Grand Ballroom A-D**

#### -omics  
**Moderated by Cameron Brennan and Howard Colman**

1:00 pm  OM-08  
Fine mapping of the germline 8q24 region associated with the development of oligodendroglioma  
Robert B. Jenkins

1:15 pm  OM-23  
Aberrant transcriptional activation is associated with gene body hypomethylation in glioblastoma  
Raman P. Nagarajan

1:30 pm  OM-21  
C/EBP-β and C/EBP-δ, master regulators of the mesenchymal transition in glioblastoma, are highly correlated with extent of necrosis and strongly expressed by hypoxic pseudopalisading cells  
Daniel J. Brat
Multidimensional integrated molecular profiling of grade II & III diffuse astrocytomas reveal distinct subclasses correlated with clinical outcome
Daniel Gorovets

miR-181d: a predictive glioblastoma biomarker that down-regulates MGMT expression
Clark Chen

Gene expression profiling of glioblastomas is more accurate than recursive partitioning analysis and MGMT methylation for predicting temozolomide responsiveness
Robert W. Cook

The effect of tumor subtype on survival and the graded prognostic assessment (GPA) for patients with breast cancer and brain metastases
Paul W. Sperduto

Metabolic characterization of glioma populations
Adam Elkhaled

Concurrent Sessions 3:15-5:00 pm

Quality of Life/Neurocognitive
Grand Ballroom A-D
Moderated by Jeffrey Wefel and Sherry Fox

Longitudinal cognitive follow-up in newly diagnosed glioblastoma patients treated with bevacizumab, temozolomide and hypofractionated stereotactic radiotherapy
Denise D. Correa

Compromised health-related quality of life in low-grade glioma patients
M. Klein

Neurocognitive function following cranial irradiation for pediatric brain tumors: A prospective study
Kristin J. Redmond

Clinical utility of neurocognitive function as a prognostic factor for survival and measure of differential between-arm treatment effects on RTOG-0525
Jeffrey S. Wefel

Prognostic importance of quality of life and fatigue in recurrent high-grade glioma patients
Katherine B. Peters

Prediction of memory outcomes after resection of high grade glioma
Jeffrey S. Wefel

Exploration of symptom clusters in patients with primary and metastatic brain cancer
Jennifer Cahill
Surgical Therapies
Grand Ballroom E-G
Moderated by Constantinos Hadjipanayis and John Boockvar

3:15 pm ST-41 The relationship between extent of resection and outcome in newly diagnosed GBM: Results from RTOG 0525
  Michael A. Vogelbaum

3:30 pm ST-04 Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis
  Philip C. De Witt Hamer

3:45 pm ST-17 Low-grade insular glioma resection with 1.5T intra-operative MRI: preliminary results of a prospective randomized trial
  Xiaolei Chen

4:00 pm ST-25 Assessing performance in brain tumor debulking using a novel virtual reality simulator
  Nicholas Gelinas-Phaneuf

4:15 pm ST-28 Stereotactic brachytherapy with 125Iodine-seeds (SBT) for treatment WHO grade II and III gliomas located in the central sulcus area
  Maximilian I. Ruge

4:30 pm RT-05 Patient outcome and response to therapy after stereotactic radiosurgery or radiotherapy for intracranial meningiomas: Emphasis on predictive biomarker discovery
  Randy L. Jensen

4:45 pm ST-07 An extent of resection threshold for recurrent glioblastomas
  Mark E. Oppenlander

Poster Viewing Reception II  5:00-7:00 pm
Royal Ballroom
Supported by Merck

Banquet  7:15 – 10:00 pm
Grand Ballroom

Sunday, November 20, 2011
7:00-9:00 am Breakfast in the Foyer

Sunrise Sessions  7:00-8:00 am

Atypical and Malignant Meningioma  Terrace A-C
- Brachytherapy for recurrent atypical and malignant meningiomas
  Michael McDermott
- Role of chemotherapy in meningiomas
  Jeffrey Raizer
- Radiation Therapy for meningiomas: Review and update
  Igor Barani

Molecular Pathology: Practice and Promise  Harbor Room
- Stratification of adult and pediatric patients with molecular pathology
  Joanna J. Phillips
- Genomics and emerging technologies in molecular pathology and trials
  Keith Ligon
- Industry perspectives on molecular pathology integration in clinical trial design
  Emmanuelle di Tomaso

Immunobiology  Pacific Room
- Glioma vaccines targeting multiple epitopes -- Hope and Challenges in Clinical Settings
  Hideo Okada
- Immunosuppressive Microenvironment:
  Allen Waziri
- Adoptive T-cell Therapy
  Stephen Gottschalk

Plenary Session  8:15-noon
Grand Ballroom

Medical and Neuro-Oncology - 1
Moderated by Andrew Lassman and Daniela Bota

8:15 am EP-11 Variation over time and inter-dependence between disease progression and death among patients with Glioblastoma(GBM) on RTOG 0525
  Meihua Wang

8:30 am NO-64 Triple-negative low-grade gliomas: A highly aggressive tumor with dismal prognosis
  Philippe Metellus

8:45 am NO-82 Phase II study of bevacizumab, temozolomide and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma
  Antonio Omuro
9:00 am OT-16 NCCTG N0272: Phase II trial of imatinib mesylate; (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. A North Central Cancer Treatment Group study
Kurt A. Jaeckle

9:15 am OT-12 A phase I study of the smoothened (Smo) antagonist LDE225 in patients with advanced solid tumors: preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity in medulloblastoma
Jordi Rodon

9:30 am NO-45 IDH mutations and their role in progression of low grade gliomas
Tareq A. Juratli

9:45 am Break

Clinical Trials Update
Moderated by W. K. Alfred Yung

10:00 – 11:00 am Clinical trials update

Medical and Neuro-Oncology - 2
Moderated by Patrick Wen and Timothy Cloughesy

11:00 am NO-116 Hearing and radiographic response of NF2-related vestibular schwannoma to bevacizumab: a retrospective review of 31 patients
Scott R. Plotkin

11:15 am OT-09 Updated survival data of the phase III clinical trial of NovoTTF-100A versus best standard chemotherapy for recurrent glioblastoma
Eric T. Wong

11:30 am EP-07 Associations of glioma risk loci by IDH mutation status
Terri Rice

11:45 am NO-74 IDH1 mutations in grade II astrocytomas are associated with unfavorable progression free survival and prolonged post-recurrence survival
Niklas Thon

Adjourn